DOI: https://doi.org/10.24959/cphj.19.1509

The study of the effect of the low molecular analog of neuropeptide Y on behavioral reactions in rats

A. L. Zagayko, I. O. Havrylov, D. V. Lytkin

Abstract


It is known that along with the main stress-adaptive systems, one of the decisive places is occupied by the biologically active peptide – neuropeptide Y (NPY). NPY is a biologically active compound of peptide nature, which is capable to activate 4 different subtypes of NPY receptors in mammals. The prevalence of NPY receptors determines that the system of NPY and NPY receptors is involved in the regulation of many physiological functions, including the feeling of satiety and hunger, circadian rhythms, response to stress, learning, regulation of the vascular tone, sleep, sexual behavior, etc.
Аim. To study the effect of the low molecular analog of neuropeptide Y on the behavioral response of rats in the tests “open field” and “elevated plus-maze”.
Materials and methods. The study object was a modified terminal NPY fragment containing 9 amino acid residues. The experimental animals received intranasally a solution of the peptide studied in the dose of 0.02 mg/kg, 0.05 mg/kg and 0.1 mg/kg. The pharmacological study of the effect of the compound on the behavioral reactions of rats was performed using the tests “open field” and “elevated plus-maze”.
Results. Experiments in rats showed the presence of anxiolytic properties of the compound without the associated sedative effect. In the tests “open field” and “elevated plus-maze”, the activating effect of the compound on the locomotor activity and a decrease in vegetative manifestations were observed.
Conclusions. The data obtained indicate that the neuropeptide Y modified fragment is able to affect the anxiety level and research activity of rats; it substantiates the feasibility of further studies of this experimental compound.


Keywords


neuropeptide Y; stress; open field; elevated plus-maze; behavioral disorders

References


Reichmann, F., & Holzer, P. (2016). Neuropeptide Y: A stressful review. Neuropeptides, 55, 99–109. https://doi.org/10.1016/j.npep.2015.09.008

Yi, M., Li, H., Wu, Z., Yan, J., Liu, Q., Ou, C., & Chen, M. (2017). A Promising Therapeutic Target for Metabolic Diseases: Neuropeptide Y Receptors in Humans. Cellular Physiology and Biochemistry, 45(1), 88–107. https://doi.org/10.1159/000486225

Benarroch, E. E. (2009). Neuropeptide Y: Its multiple effects in the CNS and potential clinical significance. Neurology, 72(11), 1016–1020. https://doi.org/10.1212/01.wnl.0000345258.18071.54

Eaton, K., Sallee, F., & Sah, R. (2007). Relevance of Neuropeptide Y (NPY) in Psychiatry. Current Topics in Medicinal Chemistry, 7(17), 1645–1659. https://doi.org/10.2174/156802607782341037

Thorsell, A., & Ehlers, C. L. (2006). Neuropeptide Y in Brain Function. Handbook of Neurochemistry and Molecular Neurobiology, 523–543. https://doi.org/10.1007/978-0-387-30381-9_23

Sabban, E. L., Alaluf, L. G., & Serova, L. I. (2016). Potential of neuropeptide Y for preventing or treating post-traumatic stress disorder. Neuropeptides, 56, 19–24. https://doi.org/10.1016/j.npep.2015.11.004

Kash, T. L., & Winder, D. G. (2006). Neuropeptide Y and corticotropin-releasing factor bi-directionally modulate inhibitory synaptic transmission in the bed nucleus of the stria terminalis. Neuropharmacology, 51(5), 1013–1022. https://doi.org/10.1016/j.neuropharm.2006.06.011

Narváez, M., Borroto-Escuela, D. O., Santín, L., Millón, C., Gago, B., Flores-Burgess, A., … Fuxe, K. (2018). A Novel Integrative Mechanism in Anxiolytic Behavior Induced by Galanin 2/Neuropeptide Y Y1 Receptor Interactions on Medial Paracapsular Intercalated Amygdala in Rats. Frontiers in Cellular Neuroscience, 12. https://doi.org/10.3389/fncel.2018.00119

Meredith, M. E., Salameh, T. S., & Banks, W. A. (2015). Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases. The AAPS Journal, 17(4), 780–787. https://doi.org/10.1208/s12248-015-9719-7

Beck-Sickinger, A. G., Weland, H. A., Wittneben, H., Willim, K.-D., Rudolf, K., & Jung, G. (1994). Complete L-Alanine Scan of Neuropeptide Y Reveals Ligands Binding to Y1 and Y2 Receptors with Distinguished Conformations. European Journal of Biochemistry, 225(3), 947–958. https://doi.org/10.1111/j.1432-1033.1994.0947b.x

Zambello, E., Zanetti, L., Hédou, G. F., Angelici, O., Arban, R., Tasan, R. O., … Caberlotto, L. (2011). Neuropeptide Y-Y2 receptor knockout mice: influence of genetic background on anxiety-related behaviors. Neuroscience, 176, 420–430. https://doi.org/10.1016/j.neuroscience.2010.10.075

Lach, G., & de Lima, T. C. M. (2013). Role of NPY Y1 receptor on acquisition, consolidation and extinction on contextual fear conditioning: Dissociation between anxiety, locomotion and non-emotional memory behavior. Neurobiology of Learning and Memory, 103, 26–33. https://doi.org/10.1016/j.nlm.2013.04.005

Tan, C. M. J., Green, P., Tapoulal, N., Lewandowski, A. J., Leeson, P., & Herring, N. (2018). The Role of Neuropeptide Y in Cardiovascular Health and Disease. Frontiers in Physiology, 9. https://doi.org/10.3389/fphys.2018.01281

Herring, N., Lokale, M. N., Danson, E. J., Heaton, D. A., & Paterson, D. J. (2008). Neuropeptide Y reduces acetylcholine release and vagal bradycardia via a Y2 receptor-mediated, protein kinase C-dependent pathway. Journal of Molecular and Cellular Cardiology, 44(3), 477–485. https://doi.org/10.1016/j.yjmcc.2007.10.001

Tran, L. V., Somogyi, G. T., & De Groat, W. C. (1994). Inhibitory effect of neuropeptide Y on adrenergic and cholinergic transmission in rat urinary bladder and urethra. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 266(4), R1411–R1417. https://doi.org/10.1152/ajpregu.1994.266.4.r1411

Quarta, D., Leslie, C. P., Carletti, R., Valerio, E., & Caberlotto, L. (2011). Central administration of NPY or an NPY-Y5 selective agonist increase in vivo extracellular monoamine levels in mesocorticolimbic projecting areas. Neuropharmacology, 60(2-3), 328–335. https://doi.org/10.1016/j.neuropharm.2010.09.016

Schlicker, E., Gro ß, G., Fink, K., Glaser, T., & Göthert, M. (1991). Serotonin release in the rat brain cortex is inhibited by neuropeptide Y but not affected by ACTH1?24 angiotensin II, bradykinin and delta-sleep-inducing peptide. Naunyn-Schmiedeberg’s Archives of Pharmacology, 343(2), 117–122. https://doi.org/10.1007/bf00168597


GOST Style Citations


1. Reichmann, F. Neuropeptide Y : A stressful review / F. Reichmann, P. Holzer // Neuropeptides. – 2015. – Vol. 55. – P. 99–109. https://doi.org/10.1016/j.npep.2015.09.008


2. A Promising Therapeutic Target for Metabolic Diseases: Neuropeptide Y Receptors in Humans / M. Yi, H. Li, Z. Wu et al. // Cell. Physiol. Biochem. – 2018. – № 45. – P. 88–107. https://doi.org/10.1159/000486225


3. Benarroch, Е. Е. Neuropeptide Y: its multiple effects in the CNS and potential clinical significance / Е. Е. Benarroch // Neurol. – 2009. – № 72. – P. 1016–1020. https://doi.org/10.1212/01.wnl.0000345258.18071.54


4. Eaton, К. Relevance of neuropeptide Y (NPY) in psychiatry / К. Eaton, F. R. Sallee, R. Sah // Curr. Top Med. Chem. – 2007. – № 7. – P. 1645–1659. https://doi.org/10.2174/156802607782341037


5. Thorsell, A. Neuropeptide Y in Brain Function / A. Thorsell, C. L. Ehlers // Handbook of Neurochemistry and Molecular Neurobiol. – 2006. – P. 523–543. https://doi.org/10.1007/978-0-387-30381-9_23


6. Sabban, Е. Potential of neuropeptide Y for preventing or treating post-traumatic stress disorder / Е. Sabban, L. Alaluf, L. Serova // Neuropeptides. – 2016. – № 56. – P. 19–24. https://doi.org/10.1016/j.npep.2015.11.004


7. Kash, T. Neuropeptide Y and corticotropin-releasing factor bidirectionally modulate inhibitory synaptic transmission in the bed nucleus of the stria terminalis / T. Kash, D. Winder // Neuropharmacol. – 2006. – № 51. – P. 1013–1022. https://doi.org/10.1016/j.neuropharm.2006.06.011


8. A Novel Integrative Mechanism in Anxiolytic Behavior Induced by Galanin 2/Neuropeptide Y Y1 Receptor Interactions on Medial Paracapsular Intercalated Amygdala in Rats / М. Narváez, D. Borroto-Escuela, L. Santín et al. // Frontiers in Cellular Neurosci. – 2018. – №12. – P. 119. https://doi.org/10.3389/fncel.2018.00119


9. Meredith, M. E. Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases / M. E. Meredith,
T. S. Salameh, W. A. Banks // AAPS J. – 2015. – № 17. – P. 780–787. https://doi.org/10.1208/s12248-015-9719-7


10. Complete L-Alanine Scan of Neuropeptide Y Reveals Ligands Binding to Y1 and Y2 Receptors with Distinguished Conformations / A. Beck-Sickinger, H. Weland, H. Wittneben et al. // European J. of Biochemistry. – 1994. – № 225. – P. 947–958. https://doi.org/10.1111/j.1432-1033.1994.0947b.x


11. Neuropeptide Y-Y2 receptor knockout mice: influence of genetic background on anxiety-related behaviors / E. Zambello, L. Zanetti, G. Hédou et al. // Neurosci. – 2011. – № 176. – P. 420–430. https://doi.org/10.1016/j.neuroscience.2010.10.075


12. Lach, G. Role of NPY Y1 receptor on acquisition, consolidation and extinction on contextual fear conditioning: Dissociation between anxiety, locomotion and non-emotional memory behavior / G. Lach, T. Lima // Neurobiol. of Learning and Memory. – 2013. – № 103. – P. 26–33. https://doi.org/10.1016/j.nlm.2013.04.005


13. The Role of Neuropeptide Y in Cardiovascular Health and Disease / C. Tan, P. Green, N. Tapoulal et al. // Frontiers in Physiol. – 2018. – № 9. – P. 1–13. https://doi.org/10.3389/fphys.2018.01281


14. Neuropeptide Y reduces acetylcholine release and vagal bradycardia via a Y2 receptor-mediated, protein kinase C-dependent pathway / N. Herring, M. Lokale, E. Danson et al. // J. of Molecular and Cellular Cardiol. – 2008. – № 44. – P. 477–485. https://doi.org/10.1016/j.yjmcc.2007.10.001


15. Tran, L. Inhibitory effect of neuropeptide Y on adrenergic and cholinergic transmission in rat urinary bladder and urethra / L. Tran, G. Somogyi, W. De Groat // American J. of Physiology-Regulatory, Integrative and Comparative Physiol. – 1994. – № 266. – P. 1411–1417. https://doi.org/10.1152/ajpregu.1994.266.4.r1411

 

16. Central administration of NPY or an NPY-Y5 selective agonist increase in vivo extracellular monoamine levels in mesocorticolimbic projecting areas / D. Quarta, C. Leslie, R. Carletti et al. // Neuropharmacol. – 2011. – № 60. – P. 328–335. https://doi.org/10.1016/j.neuropharm.2010.09.016

 

17. Serotonin release in the rat brain cortex is inhibited by neuropeptide Y but not affected by ACTH1-24 angiotensin II, bradykinin and delta-sleep-inducing peptide / E. Schlicker, G. Groß, K. Fink et al. // Naunyn-Schmiedeberg’s Archives of Pharmacol. – 1991. – № 343. – P. 117–122. https://doi.org/10.1007/bf00168597





Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Abbreviated key title: Clin. pharm.

ISSN 2518-1572 (Online), ISSN 1562-725X (Print)